Neurobo Pharmaceuticals Buy Hold or Sell Recommendation
| NRBODelisted Stock | USD 2.36 0.01 0.43% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Neurobo Pharmaceuticals is 'Strong Sell'. The recommendation algorithm takes into account all of Neurobo Pharmaceuticals' available fundamental, technical, and predictive indicators you will find on this site.
Check out Neurobo Pharmaceuticals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. In addition, we conduct extensive research on individual companies such as Neurobo and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Neurobo Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.
Neurobo |
Execute Neurobo Pharmaceuticals Buy or Sell Advice
The Neurobo recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Neurobo Pharmaceuticals. Macroaxis does not own or have any residual interests in Neurobo Pharmaceuticals or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Neurobo Pharmaceuticals' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Neurobo Pharmaceuticals Trading Alerts and Improvement Suggestions
| Neurobo Pharmaceuticals is now traded under the symbol MTVA. Please update your portfolios or report it if you believe this is an error. Report It! | |
| Neurobo Pharmaceuticals generated a negative expected return over the last 90 days | |
| Neurobo Pharmaceuticals has high historical volatility and very poor performance | |
| Neurobo Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 7 K. Net Loss for the year was (12.47 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Neurobo Pharmaceuticals currently holds about 8.85 M in cash with (10.8 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.96, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 65.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from finance.yahoo.com: NeuroBo Pharmaceuticals Announces Strategic Realignment Ahead of Important Clinical Milestones with Name Change to MetaVia - Reflecting the Companys Focus on Cardiometabolic Diseases |
Neurobo Pharmaceuticals Returns Distribution Density
The distribution of Neurobo Pharmaceuticals' historical returns is an attempt to chart the uncertainty of Neurobo Pharmaceuticals' future price movements. The chart of the probability distribution of Neurobo Pharmaceuticals daily returns describes the distribution of returns around its average expected value. We use Neurobo Pharmaceuticals price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Neurobo Pharmaceuticals returns is essential to provide solid investment advice for Neurobo Pharmaceuticals.
| Mean Return | -0.47 | Value At Risk | -7.34 | Potential Upside | 6.76 | Standard Deviation | 4.80 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Neurobo Pharmaceuticals historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Neurobo Pharmaceuticals Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Neurobo Pharmaceuticals or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Neurobo Pharmaceuticals' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Neurobo delisted stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.5 | |
β | Beta against Dow Jones | 0.19 | |
σ | Overall volatility | 4.82 | |
Ir | Information ratio | -0.13 |
Neurobo Pharmaceuticals Volatility Alert
Neurobo Pharmaceuticals exhibits very low volatility with skewness of 1.47 and kurtosis of 4.07. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Neurobo Pharmaceuticals' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Neurobo Pharmaceuticals' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Neurobo Pharmaceuticals Fundamentals Vs Peers
Comparing Neurobo Pharmaceuticals' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Neurobo Pharmaceuticals' direct or indirect competition across all of the common fundamentals between Neurobo Pharmaceuticals and the related equities. This way, we can detect undervalued stocks with similar characteristics as Neurobo Pharmaceuticals or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Neurobo Pharmaceuticals' fundamental indicators could also be used in its relative valuation, which is a method of valuing Neurobo Pharmaceuticals by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Neurobo Pharmaceuticals to competition |
| Fundamentals | Neurobo Pharmaceuticals | Peer Average |
| Return On Equity | -1.61 | -0.31 |
| Return On Asset | -0.74 | -0.14 |
| Current Valuation | (1.18 M) | 16.62 B |
| Shares Outstanding | 8.62 M | 571.82 M |
| Shares Owned By Insiders | 65.23 % | 10.09 % |
| Shares Owned By Institutions | 12.71 % | 39.21 % |
| Number Of Shares Shorted | 34.27 K | 4.71 M |
| Price To Earning | (1.44) X | 28.72 X |
| Price To Book | 1.57 X | 9.51 X |
| Revenue | 7 K | 9.43 B |
| EBITDA | (15.88 M) | 3.9 B |
| Net Income | (12.47 M) | 570.98 M |
| Cash And Equivalents | 8.85 M | 2.7 B |
| Cash Per Share | 9.96 X | 5.01 X |
| Total Debt | 203 K | 5.32 B |
| Debt To Equity | 0.01 % | 48.70 % |
| Current Ratio | 8.07 X | 2.16 X |
| Book Value Per Share | 1.50 X | 1.93 K |
| Cash Flow From Operations | (10.8 M) | 971.22 M |
| Short Ratio | 0.87 X | 4.00 X |
| Earnings Per Share | (4.29) X | 3.12 X |
| Target Price | 26.67 | |
| Number Of Employees | 8 | 18.84 K |
| Beta | -0.28 | -0.15 |
| Market Capitalization | 20.33 M | 19.03 B |
| Total Asset | 22.78 M | 29.47 B |
| Retained Earnings | (108.27 M) | 9.33 B |
| Working Capital | 16.55 M | 1.48 B |
| Current Asset | 21.62 M | 9.34 B |
| Current Liabilities | 11.75 M | 7.9 B |
| Net Asset | 22.78 M |
Note: Acquisition by Strickland D Gordon of 12500 shares of Neurobo Pharmaceuticals subject to Rule 16b-3 [view details]
Neurobo Pharmaceuticals Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Neurobo . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Neurobo Pharmaceuticals Buy or Sell Advice
When is the right time to buy or sell Neurobo Pharmaceuticals? Buying financial instruments such as Neurobo Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Neurobo Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Emerging Markets Funds Thematic Idea Now
Emerging Markets Funds
Fund or Etfs that invest in markets of developing countries. The Emerging Markets Funds theme has 44 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Emerging Markets Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Neurobo Pharmaceuticals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Other Consideration for investing in Neurobo Stock
If you are still planning to invest in Neurobo Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Neurobo Pharmaceuticals' history and understand the potential risks before investing.
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges |